These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 19845257

  • 1. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH, Oneto A, Aranda C, O'Connor JM, Domenichini E, Roca E, Méndez G, Bestani MC, Parma P, Giacomi N, Marmissolle F.
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
    Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, Rossi RE, Peracchi M.
    Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
    Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG.
    Neuroendocrinology; 2009 Sep; 89(3):296-301. PubMed ID: 18840995
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
    Modlin IM, Gustafsson BI, Drozdov I, Nadler B, Pfragner R, Kidd M.
    Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
    [Abstract] [Full Text] [Related]

  • 15. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas.
    Abou-Saif A, Gibril F, Ojeaburu JV, Bashir S, Entsuah LK, Asgharian B, Jensen RT.
    Cancer; 2003 Jul 15; 98(2):249-61. PubMed ID: 12872342
    [Abstract] [Full Text] [Related]

  • 16. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
    Bernini GP, Moretti A, Ferdeghini M, Ricci S, Letizia C, D'Erasmo E, Argenio GF, Salvetti A.
    Br J Cancer; 2001 Mar 02; 84(5):636-42. PubMed ID: 11237384
    [Abstract] [Full Text] [Related]

  • 17. [Chromogranin A and neuroendocrine tumors].
    Díaz Pérez JÁ, Currás Freixes M.
    Endocrinol Nutr; 2013 Mar 02; 60(7):386-95. PubMed ID: 23271036
    [Abstract] [Full Text] [Related]

  • 18. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
    Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM.
    J Clin Oncol; 2009 Sep 10; 27(26):4293-9. PubMed ID: 19667278
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.